Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.

To assess the efficacy and safety of intravitreous pegaptanib sodium (Macugen; EyeTech Pharmaceuticals/Pfizer Inc, New York, New York, USA) for macular edema secondary to branch retinal vein occlusion (BRVO).
Prospective, randomized, dose-finding study.
Twenty subjects from three clinical practices in the United States with BRVO of more than 1 month's and fewer than 6 months' duration; best-corrected visual acuity (BCVA) 70 to 25 Early Treatment Diabetic Retinopathy Study letters inclusive (approximately 20/40 to 20/320 Snellen); and central foveal thickness of 250 microm or more were included. Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3 or 1 mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48. Principal efficacy outcomes were change from baseline to week 54 in BCVA, center point thickness, central subfield thickness, and macular volume as measured by optical coherence tomography.
Fifteen subjects received pegaptanib 0.3 mg and 5 received pegaptanib 1 mg. Eighteen subjects completed the 54-week follow-up. Results were similar in both the 0.3- and 1-mg groups. Overall improvements from baseline to week 54 occurred in mean BCVA (+14 +/- 13 letters), center point thickness (-205 +/- 195 mum), central subfield thickness (-201 +/- 153 mum), and macular volume (-2.2 +/- 1.6 mm(3)). The response was rapid after the first injection, with a mean BCVA improvement of 11 +/- 7 letters at 1 week from the baseline of 56 +/- 12 letters (approximately 20/80 Snellen). One retinal detachment and no cases of endophthalmitis or traumatic cataract were seen.
Intravitreous pegaptanib offers a promising alternative as a treatment for macular edema secondary to BRVO.
AuthorsJohn J Wroblewski, John A Wells 3rd, Christine R Gonzales
JournalAmerican journal of ophthalmology (Am J Ophthalmol) Vol. 149 Issue 1 Pg. 147-54 (Jan 2010) ISSN: 1879-1891 [Electronic] United States
PMID19875087 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2010 Elsevier Inc. All rights reserved.
Chemical References
  • Aptamers, Nucleotide
  • Vascular Endothelial Growth Factor A
  • pegaptanib
  • Aged
  • Aged, 80 and over
  • Aptamers, Nucleotide (administration & dosage)
  • Female
  • Humans
  • Injections
  • Macular Edema (drug therapy, etiology, physiopathology)
  • Male
  • Middle Aged
  • Prospective Studies
  • Retina (pathology)
  • Retinal Vein Occlusion (complications, drug therapy, physiopathology)
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Visual Acuity (physiology)
  • Vitreous Body

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: